BACE/APPV717F Double-Transgenic Mice Develop Cerebral Amyloidosis and Inflammation

Authors:
  • MWMarie Woolley
    Marie Woolley
  • AAAnita Albientz
    Anita Albientz
  • MTMarie- Therese
    Marie- Therese
  • PNPeter Nelboeck
    Peter Nelboeck
  • PMPari Malherbe
    Pari Malherbe
  • FGFiona Grüninger-Leitch
    Fiona Grüninger-Leitch
  • MBManfred Brockhaus
    Manfred Brockhaus
  • TBTheresa Ballard
    Theresa Ballard
  • HJHelmut Jacobsen
    Helmut Jacobsen

Abstract
Most of the transgenic mice generated to model Alzheimer’s disease express human amyloid precursor protein (APP) mutants alone or in conjunction with presenilin mutants. We have generated a mouse model by overexpressing human BACE and human APP with the V717F mutation. The combination of a mutation at the γ-secretase cleavage site of APP and of increased β-secretase activity should favour the production of amyloid peptides. We analysed double BACE/APPIn and single APPIn transgenic mice at 16–18 months for amyloid load, brain histopathology and behavioural deficits. We show that overexpression of BACE induces an increase in APP CTFβ and total brain Aβ peptides. Brain histopathology shows clearly enhanced amyloid deposits in the cortex, hippocampus and in brain vasculature when compared to single APPIn transgenic mice. Amyloid deposits are mostly diffuse and predominantly composed of Aβ42. A strong inflammatory reaction is evidenced by the presence of microglial cells around the most mature amyloid deposits and astrocytosis over the entire cerebral cortex. At the same age, the APPIn single-transgenic mice show only very limited pathology. When assessed for their cognitive performance at 12 months, BACE/APPIn mice show impaired spatial acquisition in the Morris water maze test. However, these deficits are not greater than those observed in the APPIn single-transgenic animals.

This publication has 53 references indexed in Scilit: